HOME Press Releases Research Antibodies Market worth 12.60 Billion USD by 2022



Research Antibodies Market worth 12.60 Billion USD by 2022


The report "Research Antibodies Market by Product (Antibodies (Primary, Secondary)(Mouse, Rabbit)), Reagents), Technology (Western Blot, Flow Cytometry, Elisa, Immunoflourescence, Immunohistochemistry), Application, & End User - Global Forecast to 2022", analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Browse 187 Market Data Tables and 42 Figures spread through 279 Pages and in-depth TOC on "Research Antibodies Market by Product (Antibodies (Primary, Secondary)(Mouse, Rabbit)), Reagents), Technology (Western Blot, Flow Cytometry, Elisa, Immunoflourescence, Immunohistochemistry), Application, & End User - Global Forecast to 20222"
https://www.marketsandmarkets.com/Market-Reports/research-antibodies-reagents-market-94212793.html
Early buyers will receive 10% customization on reports.

The research antibodies market (including reagents) is expected to reach USD 12.60 Billion by 2022 from an estimated USD 9.33 Billion in 2017, at a CAGR of 6.2% during the forecast period. Factors such as the increasing R&D activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and the growing collaboration between industries and academic institutes are the key drivers of the research antibodies market. However, the quality concerns over research antibodies (with respect to research reproducibility), cost- and time- intensive antibody development processes, and the pricing pressures faced by prominent market players are the major challenges currently at play in the market

By product, the reagents segment accounted for the largest share of the market

On the basis of product, the reagents segment accounted for the largest share of the global research antibodies market (including reagents), in 2016. This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.

The western blotting segment dominated the market in 2016

Based on technology, the western blotting segment accounted for the largest share of the research antibodies market. Its ability to quantify as little as 0.1 nanograms of protein in a sample with high specificity makes it an indispensable tool in proteomic research; this is the key factor driving market growth.

The proteomics segment held the largest market share in 2016

Based on application, the proteomics segment accounted for the largest share of the research antibodies market. The large share of this segment is attributed to the deployment of proteomic-based approaches in biomarker detection and cancer profiling, increasing R&D expenditure, and availability of funds from various organizations.

Pharmaceutical & biotechnological companies held the largest market share in 2016

Based on end user, the pharmaceutical & biotechnological companies segment accounted for the largest share of the research antibodies market owing to the high uptake of research-specific antibodies in the drug discovery and development process, along with the increasing use of these research tools in the ever-developing proteomics research sector.

North America dominated the market in 2016

North America accounted for the largest share of the research antibodies market in 2016, followed by Europe. This regional segment shows significant market growth opportunities owing to the increasing research activities in the fields of proteomics and genomics, favorable government funding initiatives, and the growing focus of stakeholders on research projects.

The major players in the research antibodies market (including reagents) are Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports